<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Histotype-Dependent Autoimmune Susceptibility Theory - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-50</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-50</p>
                <p><strong>Name:</strong> Histotype-Dependent Autoimmune Susceptibility Theory</p>
                <p><strong>Type:</strong> specific</p>
                <p><strong>Theory Query:</strong> Build a theory that explains the high rate of autoimmunity among patients with thymomas, based on the following results.</p>
                <p><strong>Description:</strong> Different WHO histologic types of thymoma confer distinct risks and patterns of autoimmune disease through histotype-specific differences in residual thymopoietic capacity, thymocyte maturation stage composition, metabolic pathway activation, and degree of epithelial-lymphocyte interaction. B2 and B3 (cortical) thymomas with abundant immature thymocytes show highest autoimmune risk through active thymopoiesis with defective selection, while type A thymomas with minimal lymphocytes show lowest risk due to absent or minimal functional thymic selection. The specific pattern of autoimmune diseases also varies by histotype, with some conditions showing strong preferences for particular WHO types.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Thymopoietic Capacity Determines Autoimmune Risk</h3>
            <p><strong>Statement:</strong> Thymoma histotypes that retain active thymopoietic capacity with presence of early thymic progenitors (ETPs), CD4 immature single positive (ISP), and double-positive (DP) thymocytes exhibit higher rates of autoimmunity overall, with B2 and B3 thymomas showing the strongest associations with MG and other autoimmune conditions. Type A thymomas with predominantly epithelial composition and minimal thymocytes show minimal autoimmune association. The absolute number of immature thymocytes and their maturation capacity within the tumor correlates with autoimmune disease prevalence.</p>
            <p><strong>Domain/Scope:</strong> Applies across the WHO classification spectrum of thymomas (A, AB, B1, B2, B3) in relation to autoimmune disease prevalence, measured at time of diagnosis or during active disease. Most clearly demonstrated for myasthenia gravis but extends to other T-cell-dependent autoimmune conditions. Thymic carcinomas (type C) excluded as they lack functional thymopoietic capacity and show minimal autoimmune associations.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Type AB represents an intermediate phenotype with mixed epithelial and lymphocytic features, showing intermediate autoimmune risk</li>
                <li>Individual tumors may show intratumoral heterogeneity that does not align with overall WHO classification</li>
                <li>Invasive/advanced stage thymomas (Masaoka stage III/IV) may lose thymopoietic capacity due to architectural disruption regardless of initial histotype</li>
                <li>Very small thymomas detected incidentally may not have had sufficient time or volume to export significant numbers of autoreactive cells</li>
                <li>Some type A thymomas occasionally associate with autoimmunity despite minimal lymphocytes, suggesting epithelial factors may contribute in rare cases</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>MG associated mainly with WHO types B1, B2, B3 > AB > A, with cortical/lymphocyte-rich thymomas predominating; type B thymoma (especially B2) more likely to be complicated with MG. <a href="../results/extraction-result-191.html#e191.0" class="evidence-link">[e191.0]</a> <a href="../results/extraction-result-182.html#e182.1" class="evidence-link">[e182.1]</a> <a href="../results/extraction-result-190.html#e190.1" class="evidence-link">[e190.1]</a> <a href="../results/extraction-result-180.html#e180.0" class="evidence-link">[e180.0]</a> </li>
    <li>WHO types B1 and B2 specifically linked to MG in multiple studies and clinical series. <a href="../results/extraction-result-190.html#e190.1" class="evidence-link">[e190.1]</a> <a href="../results/extraction-result-180.html#e180.0" class="evidence-link">[e180.0]</a> </li>
    <li>Presence of active thymopoiesis (ETPs, CD4ISP and DP thymocytes) documented in thymomas; MG+ thymomas show increased intratumoral naive CD3+CD4+CD45RA+ T cells. <a href="../results/extraction-result-191.html#e191.0" class="evidence-link">[e191.0]</a> </li>
    <li>MG+ thymomas contain significantly larger numbers of mature 'pre-emigrant' CD4+CD27+CD45RA+ cells (24.4±18.9%) versus MG- thymomas (4.3±2.0%), p<0.0001. <a href="../results/extraction-result-180.html#e180.0" class="evidence-link">[e180.0]</a> </li>
    <li>B1/B2 thymomas contain many CD4+/CD8+ double-positive (immature) thymocytes; thymomas show high Ki67 proliferation (35-80%) indicating active thymopoiesis. <a href="../results/extraction-result-190.html#e190.1" class="evidence-link">[e190.1]</a> </li>
    <li>Residual/active thymopoiesis within thymomas producing immature thymocyte populations (ETP/CD34+, CD4ISP, DP) correlates with autoimmune risk. <a href="../results/extraction-result-191.html#e191.0" class="evidence-link">[e191.0]</a> <a href="../results/extraction-result-191.html#e191.3" class="evidence-link">[e191.3]</a> </li>
    <li>Accumulation of immature thymocyte populations (ETP/CD34+, CD4ISP, DP) in thymomas; MG+ tumors show increased intratumoral naive CD4+ T cells. <a href="../results/extraction-result-191.html#e191.0" class="evidence-link">[e191.0]</a> </li>
    <li>Thymomas retain the capacity for terminal thymopoiesis and generate/export mature naive CD4+ (and CD8+) T cells, which is preserved in MG+ cases. <a href="../results/extraction-result-180.html#e180.0" class="evidence-link">[e180.0]</a> </li>
    <li>Pure red cell aplasia associated most with AB > B2, B1 > A, B3 histotypes. <a href="../results/extraction-result-191.html#e191.5" class="evidence-link">[e191.5]</a> </li>
    <li>Neuromyotonia (Isaac's syndrome) associated with B2, B3, AB histotypes and occasionally thymic carcinoma. <a href="../results/extraction-result-191.html#e191.1" class="evidence-link">[e191.1]</a> </li>
    <li>Polymyositis associated mainly with B1, B2 histotypes. <a href="../results/extraction-result-191.html#e191.3" class="evidence-link">[e191.3]</a> </li>
    <li>Good syndrome (hypogammaglobulinemia) more frequent in B2 > AB, B1, B3 > A histotypes. <a href="../results/extraction-result-191.html#e191.4" class="evidence-link">[e191.4]</a> </li>
    <li>Limbic encephalitis reported in association with A, B1, B2, B3 histotypes. <a href="../results/extraction-result-191.html#e191.2" class="evidence-link">[e191.2]</a> </li>
    <li>SLE co-presence associated primarily with B2 > AB, A histotypes. <a href="../results/extraction-result-191.html#e191.6" class="evidence-link">[e191.6]</a> </li>
    <li>Sjögren's syndrome rare association with B1 histotype. <a href="../results/extraction-result-191.html#e191.8" class="evidence-link">[e191.8]</a> </li>
    <li>Rheumatoid arthritis associated with B1, B3 histotypes. <a href="../results/extraction-result-191.html#e191.7" class="evidence-link">[e191.7]</a> </li>
    <li>Approximately 30% of patients with thymoma present with autoimmune and paraneoplastic syndromes at diagnosis; thymic carcinomas are much less commonly associated with autoimmunity. <a href="../results/extraction-result-189.html#e189.0" class="evidence-link">[e189.0]</a> </li>
    <li>Thymic carcinomas (TC) lack immature T-cell infiltrates versus thymomas (TM), which contain immature intratumoral thymocytes. <a href="../results/extraction-result-189.html#e189.1" class="evidence-link">[e189.1]</a> </li>
    <li>Type A thymomas occasionally associate with autoimmunity though rarely, suggesting factors beyond thymopoiesis may contribute in some cases. <a href="../results/extraction-result-191.html#e191.0" class="evidence-link">[e191.0]</a> </li>
    <li>TAMG cases in study cohort were frequently WHO type B2 (~44% of TAMG cases). <a href="../results/extraction-result-184.html#e184.0" class="evidence-link">[e184.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> While the clinical histotype-MG association is well-established, the specific mechanistic principle that residual active thymopoiesis (not just total lymphocyte abundance) determines risk through export of inadequately selected thymocytes represents a functional rather than purely descriptive classification, supported by quantitative T-cell subset analysis.</p>            <p><strong>What Already Exists:</strong> The clinical observation that B-type thymomas (especially B2/B3) are more strongly associated with MG than type A thymomas has been recognized since the WHO classification was adopted in the 1990s and documented in multiple clinical series.</p>            <p><strong>What is Novel:</strong> The explicit mechanistic linking of active thymopoietic capacity (measured by presence of specific immature populations: ETP, ISP, DP) as the quantitative determinant of autoimmune risk across histotypes provides a biological explanation that can predict risk based on functional capacity rather than morphology alone, and extends beyond MG to explain diverse autoimmune manifestations.</p>
        <p><strong>References:</strong> <ul>
    <li>Okumura et al. (2008) WHO histologic classification and MG [Established clinical histotype-MG associations]</li>
    <li>Strobel et al. (2004) Thymoma WHO classification [Original clinical correlations of histotypes with outcomes]</li>
    <li>Radovich et al. (2018) TCGA thymoma study [Molecular characterization by histotype but not mechanistic thymopoiesis link]</li>
    <li>Buckley et al. (2001) Mature T cells from thymomas [Early description of T cell export but not quantitative histotype correlation]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Histotype-Specific Metabolic and Immune Microenvironment Divergence</h3>
            <p><strong>Statement:</strong> MG-associated molecular pathways show opposite patterns of enrichment in AB versus B2 thymomas: oxidative phosphorylation is upregulated in MG+ AB thymomas but downregulated in MG+ B2 thymomas; macrophage polarization markers (MacTh1 cluster) are downregulated in MG+ AB but upregulated in MG+ B2. These metabolic and immune microenvironment differences likely affect thymocyte selection efficiency, survival/apoptosis decisions, and egress rates in histotype-specific ways, suggesting that different histotypes reach the same autoimmune outcome (MG) through distinct metabolic and immunological routes.</p>
            <p><strong>Domain/Scope:</strong> Applies specifically to type AB and type B2 thymomas with and without MG, based on transcriptomic pathway analysis of bulk tumor tissue. The principle may extend to other histotypes but current data is primarily from AB and B2 comparisons. Applies to molecular pathway-level differences rather than individual gene expression. Most relevant to understanding mechanisms in resectable thymomas with intact tissue architecture.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>These pathway differences may partially reflect underlying baseline histotype biology rather than MG-specific effects, requiring careful MG+/MG- comparison within each histotype</li>
                <li>Individual tumors show substantial intratumoral heterogeneity that may not be captured by bulk transcriptomic signatures</li>
                <li>Pathway enrichment analysis indicates statistical association but does not prove functional causation of autoimmunity</li>
                <li>Advanced/invasive thymomas with disrupted architecture may not show these patterns</li>
                <li>The olfactory transduction pathway upregulation in MG+ B2 may represent a non-specific autoimmune-associated signature also seen in other conditions (e.g., rheumatoid arthritis)</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Oxidative phosphorylation pathway upregulated in MG+ AB thymomas but downregulated in MG+ B2 thymomas; MacTh1 cluster (macrophage polarization marker) down in MG+ AB and up in MG+ B2. <a href="../results/extraction-result-228.html#e228.0" class="evidence-link">[e228.0]</a> </li>
    <li>Gene-set/pathway differences between MG+ and MG- thymomas are largely histotype-specific, with distinct patterns in AB versus B2 rather than universal MG signatures. <a href="../results/extraction-result-228.html#e228.0" class="evidence-link">[e228.0]</a> </li>
    <li>Histotype-specific enrichment differences in oxidative phosphorylation and MacTh1 may modulate antigen presentation, T cell selection/apoptosis decisions, and egress from the tumor. <a href="../results/extraction-result-228.html#e228.0" class="evidence-link">[e228.0]</a> </li>
    <li>Olfactory transduction pathway upregulated in MG+ B2 thymomas; this pathway has been associated with rheumatoid arthritis in other studies, suggesting possible shared autoimmune pathway. <a href="../results/extraction-result-228.html#e228.0" class="evidence-link">[e228.0]</a> <a href="../results/extraction-result-228.html#e228.2" class="evidence-link">[e228.2]</a> </li>
    <li>TCGA comparison showed MG+ thymomas did not differentially express classic immunotolerance genes versus MG- thymomas universally across histotypes. <a href="../results/extraction-result-189.html#e189.1" class="evidence-link">[e189.1]</a> </li>
    <li>MG+ thymomas overexpressed genes coding for mid-sized neurofilament and ryanodine receptor III proteins (molecular mimicry hypothesis), but expression patterns varied by histotype. <a href="../results/extraction-result-189.html#e189.1" class="evidence-link">[e189.1]</a> </li>
    <li>Some metabolic and Alzheimer-related KEGG pathways enriched in TAMG-associated thymomas are also enriched in lupus nephritis, suggesting non-specific pathway involvement in systemic autoimmunity. <a href="../results/extraction-result-228.html#e228.1" class="evidence-link">[e228.1]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: green; font-weight: bold;">new</span></p>
        <p><strong>Explanation:</strong> This law identifies a paradoxical pattern where the same autoimmune outcome associates with opposite metabolic and immune polarization states in different histotypes, suggesting multiple mechanistic routes to autoimmunity that are fundamentally determined by histotype biology rather than a shared MG signature.</p>            <p><strong>What Already Exists:</strong> General differences in gene expression between thymoma histotypes have been described in TCGA and other molecular studies, and metabolic reprogramming in cancer is well-established. Pathway analysis of thymomas has been performed.</p>            <p><strong>What is Novel:</strong> The specific observation that MG-associated pathways show opposite patterns (upregulation vs downregulation of identical metabolic and immune pathways) in AB versus B2 histotypes is novel and suggests that different histotypes employ distinct metabolic and immunologic mechanisms to produce the same autoimmune clinical outcome, challenging the idea of a single MG pathway.</p>
        <p><strong>References:</strong> <ul>
    <li>Radovich et al. (2018) TCGA thymoma [Comprehensive molecular characterization by histotype but no MG-specific pathway divergence described]</li>
    <li>Rajan et al. (2020) TAMG pathway analysis [First systematic description of histotype-specific MG pathways showing opposite enrichment patterns]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Thymocyte Maturation Stage Composition Predicts Autoimmune Lineage Skewing</h3>
            <p><strong>Statement:</strong> MG+ thymomas show skewing of intratumoral thymopoiesis toward the CD4 lineage with accumulation of mature CD4+ single-positive T cells, whereas MG- thymomas show relative skewing toward the CD8 lineage. The CD4:CD8 lineage balance of maturing and exported thymocytes within the tumor predicts the type of autoimmune manifestation: CD4-skewed tumors preferentially export autoreactive helper T cells that support B cell autoantibody production (manifesting as MG, pemphigus, or other antibody-mediated diseases), while CD8-skewed or balanced tumors may export cytotoxic T cells contributing to cell-mediated organ-specific autoimmunity (such as alopecia areata or hepatitis).</p>
            <p><strong>Domain/Scope:</strong> Applies to B-type thymomas with retained thymopoietic capacity (B1, B2, B3 primarily), where thymopoiesis is active enough to generate meaningful numbers of single-positive CD4+ or CD8+ T cells. Most clearly demonstrated in MG+ versus MG- thymoma comparisons. May extend to other autoimmune conditions with different T cell lineage requirements. Does not apply to type A thymomas with minimal lymphocytes or to thymic carcinomas lacking thymopoiesis.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some autoimmune conditions may require both CD4+ and CD8+ T cell contributions (e.g., alopecia areata showing both CD4 and CD8 infiltration around hair follicles)</li>
                <li>CD8-skewed thymomas may contribute to non-antibody-mediated autoimmune diseases that are less commonly reported in association with thymoma</li>
                <li>Lineage skewing may change over time with tumor evolution or may be affected by tumor stage and architecture</li>
                <li>Mixed CD4/CD8 export may occur in AB or B1 thymomas with heterogeneous thymopoietic activity</li>
                <li>The relationship between intratumoral lineage skewing and peripheral manifestations assumes that exported T cells maintain their lineage commitment and function peripherally</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>MG+ thymomas show increased intratumoral naive CD3+CD4+CD45RA+ T cells and skewing toward CD4 lineage commitment; MG- thymomas show skewing toward CD8 lineage. <a href="../results/extraction-result-191.html#e191.0" class="evidence-link">[e191.0]</a> </li>
    <li>Skewing of intratumoral T-cell maturation favoring CD4+ lineage may permit escape/expansion of autoreactive helper T cells that support pathogenic B cell responses in myasthenia gravis. <a href="../results/extraction-result-191.html#e191.0" class="evidence-link">[e191.0]</a> </li>
    <li>MG+ thymomas contain significantly larger numbers of mature 'pre-emigrant' CD4+CD27+CD45RA+ cells (24.4±18.9%) compared to MG- thymomas (4.3±2.0%), p<0.0001. <a href="../results/extraction-result-180.html#e180.0" class="evidence-link">[e180.0]</a> </li>
    <li>CD4+ T cells play a central role in MG pathogenesis in thymoma, initiating autoantibody (anti-AChR) responses; this is a CD4+ T cell-dependent process. <a href="../results/extraction-result-187.html#e187.1" class="evidence-link">[e187.1]</a> <a href="../results/extraction-result-228.html#e228.0" class="evidence-link">[e228.0]</a> <a href="../results/extraction-result-182.html#e182.0" class="evidence-link">[e182.0]</a> </li>
    <li>Egress of CD4+ effector T cells that mature inside a non-tolerogenic thymoma microenvironment leads to peripheral autoimmunity in MG. <a href="../results/extraction-result-228.html#e228.0" class="evidence-link">[e228.0]</a> </li>
    <li>Alopecia areata case (non-MG autoimmunity) showed perilesional aggregation of both CD4+ and CD8+ T cells around hair follicles, with increased CD8+ T cell counts in thymoma tissue. <a href="../results/extraction-result-187.html#e187.0" class="evidence-link">[e187.0]</a> </li>
    <li>Thymoma tissue from alopecia areata case showed dense lymphocytic infiltration with increased CD8+ T cells, contrasting with predominantly CD4-mediated MG pathogenesis. <a href="../results/extraction-result-187.html#e187.0" class="evidence-link">[e187.0]</a> </li>
    <li>Thymoma in AA case showed increased density of thymic epithelial cells and increased CD8+ T cells, with autoreactive CD8+ T cells proposed to attack hair-follicle antigens. <a href="../results/extraction-result-187.html#e187.0" class="evidence-link">[e187.0]</a> </li>
    <li>B1/B2 thymomas (high MG association) contain many CD4+/CD8+ double-positive (immature) thymocytes that can mature into either lineage. <a href="../results/extraction-result-190.html#e190.1" class="evidence-link">[e190.1]</a> </li>
    <li>Reduced mature CD4+ T-cell fraction in thymic tissue of some thymomas compared to normal thymus, with altered peripheral T-cell subset composition. <a href="../results/extraction-result-190.html#e190.1" class="evidence-link">[e190.1]</a> </li>
    <li>Thymomas produce both mature, long-lived CD4+ and CD8+ T cells that can persist in periphery. <a href="../results/extraction-result-188.html#e188.1" class="evidence-link">[e188.1]</a> <a href="../results/extraction-result-188.html#e188.2" class="evidence-link">[e188.2]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> This law provides a mechanistic prediction linking quantifiable intratumoral T cell lineage composition to specific autoimmune phenotypes, which represents an advance from knowing that 'MG involves CD4 cells' to predicting disease type from tumor T cell composition. The AA case provides preliminary support for CD8-associated non-antibody disease.</p>            <p><strong>What Already Exists:</strong> CD4+ T cell involvement in MG pathogenesis is well-established for decades, and thymomas producing different T cell populations has been described. The concept that thymomas export T cells is known.</p>            <p><strong>What is Novel:</strong> The specific principle that intratumoral CD4 versus CD8 lineage skewing predicts the type of autoimmune manifestation (antibody-mediated versus cell-mediated) provides a unified predictive framework for understanding why different patients develop different autoimmune phenotypes, going beyond the established fact that MG is CD4-dependent to predict other disease patterns.</p>
        <p><strong>References:</strong> <ul>
    <li>Strobel et al. (2004) Thymoma WHO classification [Described CD4/CD8 content differences by histotype but not predictive relationship]</li>
    <li>Buckley et al. (2001) Mature T cells from thymomas [Characterized T cell export but not lineage-disease relationship]</li>
    <li>Yamada et al. (2017) Regulatory T cells in thymoma [Discussed CD4+ populations but not lineage skewing principle]</li>
    <li>Marx et al. (2003) Thymoma-associated MG [Established CD4 role in MG but not comparative lineage framework]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Quantitative flow cytometric assessment of ETP, CD4ISP, and DP thymocyte populations within fresh thymoma tissue should predict autoimmune risk independent of morphologic WHO classification, with thymomas showing >20% immature thymocytes predicting >40% autoimmune disease rate</li>
                <li>The CD4:CD8 ratio among single-positive mature thymocytes within thymoma tissue should quantitatively predict type of autoimmunity: ratios >2:1 predict antibody-mediated diseases (MG, pemphigus) with >70% specificity, while ratios <1:1 predict cell-mediated diseases</li>
                <li>Type A thymomas should show <5% rate of T-cell-mediated autoimmunity across large cohorts regardless of AIRE expression status, confirming thymopoiesis requirement</li>
                <li>Within B2 thymomas, those with highest oxidative phosphorylation pathway scores should show higher CD4:CD8 ratios and higher MG rates than B2 thymomas with low scores</li>
                <li>Mixed AB histotype thymomas should show intermediate autoimmune risk (15-25%) and intermediate CD4:CD8 export profiles between type A (<5%) and B2 (>40%)</li>
                <li>Thymomas with high Ki67 proliferation indices (>50%) should correlate with higher rates of autoimmunity across histotypes due to more active thymopoiesis</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Therapeutic metabolic manipulation of tumors (e.g., oxidative phosphorylation pathway inhibition in AB thymomas or enhancement in B2 thymomas) might selectively reduce autoimmunity without requiring tumor resection, potentially allowing immunomodulation while preserving the gland</li>
                <li>Inducing pharmacologic or genetic differentiation of B2/B3 thymomas toward more epithelial (type A-like) phenotypes might reduce their thymopoietic capacity and prevent or reverse autoimmune complications</li>
                <li>The opposite metabolic states required for MG development in AB versus B2 thymomas might necessitate opposite therapeutic approaches (oxidative phosphorylation modulation), potentially explaining why some immunomodulatory treatments work in one histotype subset but not another</li>
                <li>Serial biopsies tracking histotype evolution over time (if thymomas can transition between types) might reveal dynamic autoimmune risk profiles, with transitions toward more lymphocyte-rich types increasing risk</li>
                <li>Transplanting thymic epithelial cells from type A thymomas into B2 thymomas might reduce thymopoietic capacity and autoimmune risk through dominant-negative effects on T cell maturation</li>
                <li>The CD4:CD8 skewing pattern might be therapeutically reversible through Notch pathway modulation or other lineage-specification interventions, potentially redirecting autoimmune phenotypes</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>Finding type A thymomas with high rates (>20%) of T-cell-mediated autoimmunity despite minimal lymphocyte content would fundamentally challenge the thymopoietic capacity model</li>
                <li>Demonstrating that thymomas with identical thymopoietic capacity (same percentage of ETP/ISP/DP cells) but different WHO histotypes show significantly different autoimmune rates would question the primacy of thymopoiesis in determining risk</li>
                <li>Showing that metabolic pathway profiles (oxidative phosphorylation, glycolysis) do not cluster by histotype in MG+ cases would challenge the histotype-specific mechanism hypothesis</li>
                <li>Finding equal frequencies of CD4-skewed and CD8-skewed thymomas among MG+ cases would undermine the lineage prediction model</li>
                <li>Demonstrating that type A thymomas expressing high levels of muscle antigens (CHRNA1, titin, RYR) produce MG at similar rates to B2 thymomas would challenge the necessity of active thymopoiesis for autoantibody disease</li>
                <li>Finding that thymic carcinomas with forced expression of thymopoietic factors still do not produce autoimmunity would suggest additional requirements beyond thymopoiesis</li>
                <li>Showing that ablation of thymopoietic capacity in B2 thymomas (while preserving tumor mass) does not reduce autoimmune manifestations would question causality</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>The theory does not fully explain why substantial proportions (40-70%) of B2/B3 thymomas with high thymopoietic capacity never develop any clinically apparent autoimmunity despite presumably exporting autoreactive T cells </li>
    <li>Within-histotype variability in autoimmune risk remains substantial and is not fully explained by thymopoietic capacity measurements alone, suggesting additional factors (genetic, stage, microenvironment) play important roles </li>
    <li>Good syndrome shows a distinct histotype preference pattern (B2 > AB, B1, B3 > A) that overlaps with but differs from MG, suggesting B cell depletion mechanisms may be partially independent of thymopoietic capacity alone <a href="../results/extraction-result-191.html#e191.4" class="evidence-link">[e191.4]</a> </li>
    <li>Some rare autoimmune associations show unexpected histotype patterns: Sjögren's syndrome with B1 specifically, rheumatoid arthritis with B1/B3, which don't clearly fit the thymopoietic capacity gradient <a href="../results/extraction-result-191.html#e191.8" class="evidence-link">[e191.8]</a> <a href="../results/extraction-result-191.html#e191.7" class="evidence-link">[e191.7]</a> </li>
    <li>Type AB thymomas show high PRCA rates (AB > B2, B1 > A, B3) despite intermediate thymopoietic capacity, suggesting disease-specific susceptibility factors beyond general thymopoiesis <a href="../results/extraction-result-191.html#e191.5" class="evidence-link">[e191.5]</a> </li>
    <li>The mechanism by which opposite metabolic states in AB versus B2 thymomas both lead to MG (rather than different autoimmune diseases) is not explained <a href="../results/extraction-result-228.html#e228.0" class="evidence-link">[e228.0]</a> </li>
    <li>The theory does not address why thymectomy outcomes vary unpredictably for autoimmune conditions despite removal of the thymopoietic source <a href="../results/extraction-result-191.html#e191.0" class="evidence-link">[e191.0]</a> </li>
    <li>The specific time course required for thymopoietic export to produce sufficient peripheral autoreactive cells for clinical disease is not defined </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>